Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 1664, Suchdauer: 0.72s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial

von Lorusso, Domenica ; Gladieff, Laurence ; O'Malley, David M ; et al.

In The Lancet 18-24 April 2026 407(10538):1513-1524
- View full text via DOI
Merkliste

2
Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations

von Kaya, Merve ; Lin, Lawrence H. ; Oosting, Jan ; et al.

In Modern Pathology June 2026 39(6)
- View full text via DOI
Merkliste

3
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

von Post, Cathalijne C B ; de Boer, Stephanie M ; Powell, Melanie E ; et al.

In The Lancet Oncology October 2025 26(10):1370-1381
- View full text via DOI
Merkliste

4
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial

von Ledermann, Jonathan A. ; Lortholary, Alain ; Penson, Richard T. ; et al.

In International Journal of Gynecological Cancer February 2026
- View full text via DOI
Merkliste

5
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

von Olawaiye, Alexander B ; Gladieff, Laurence ; O'Malley, David M ; et al.

In The Lancet 21-27 June 2025 405(10496):2205-2216
- View full text via DOI
Merkliste

6
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results

von O'Malley, David M. ; Bariani, Giovani M. ; Cassier, Philippe A. ; et al.

In Gynecologic Oncology February 2025 193:130-135
- View full text via DOI
Merkliste

7
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

von Barretina-Ginesta, Pilar ; Bennett, Katherine ; Berek, Jonathan ; et al.

In The Lancet Oncology September 2024 25(9):e420-e431
- View full text via DOI
Merkliste

8
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

von Wakkerman, Famke C ; Wu, Jiqing ; Putter, Hein ; et al.

In The Lancet Oncology June 2024 25(6):779-789
- View full text via DOI
Merkliste

9
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation

von Kaya, Merve ; Post, Cathalijne C.B. ; Tops, Carli M. ; et al.

In Modern Pathology March 2024 37(3)
- View full text via DOI
Merkliste

10
Prediction of recurrence risk in endometrial cancer with multimodal deep learning

von Volinsky-Fremond, Sarah ; Horeweg, Nanda ; Andani, Sonali ; et al.

Nature Medicine. 30(7):1962-1973
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

11
Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare

von Stark, Zornitza ; Boughtwood, Tiffany ; Haas, Matilda ; et al.

In The American Journal of Human Genetics 2 March 2023 110(3):419-426
- View full text via DOI
Merkliste

12
Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts

von Fremond, Sarah ; Andani, Sonali ; Barkey Wolf, Jurriaan ; et al.

In The Lancet Digital Health February 2023 5(2):e71-e82
- View full text via DOI
Merkliste

13
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study

von Westphalen, C.B. ; Federer-Gsponer, J. ; Pauli, C. ; et al.

In ESMO Open December 2023 8(6)
- View full text via DOI
Merkliste

14
p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

von Vermij, Lisa ; Léon-Castillo, Alicia ; Singh, Naveena ; et al.

In Modern Pathology October 2022 35(10):1475-1483
- View full text via DOI
Merkliste

15
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study

von O'Malley, D.M. ; Bariani, G.M. ; Cassier, P.A. ; et al.

In Gynecologic Oncology August 2022 166(2):245-253
- View full text via DOI
Merkliste

16
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

von Krämer, A. ; Bochtler, T. ; Pauli, C. ; et al.

In Annals of Oncology March 2023 34(3):228-246
- View full text via DOI
Merkliste

17
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

von Burdett, Nikki L. ; Willis, Madelynne O. ; Alsop, Kathryn ; et al.

Nature Genetics. 55(3):437-450
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

18
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)

von Edmondson, R.J. ; O'Connell, R.L. ; Banerjee, S. ; et al.

In Gynecologic Oncology December 2021 163(3):524-530
- View full text via DOI
Merkliste

19
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

von Vermij, Lisa ; Jobsen, Jan J. ; León-Castillo, Alicia ; et al.

British Journal of Cancer. 128(7):1360-1368
- Zum Volltext in PubMed Central
Merkliste

20
Women with gynaecological cancer awaiting radiotherapy: Self-reported wellbeing, general psychological distress, symptom distress, sexual function, and supportive care needs

von Gough, Karla ; Bergin, Rebecca Jane ; Drosdowsky, Allison ; et al.

In Gynecologic Oncology October 2022 167(1):42-50
- View full text via DOI
Merkliste

21
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study

von Shapira-Frommer, Ronnie ; Mileshkin, Linda ; Manzyuk, Ludmila ; et al.

In Gynecologic Oncology August 2022 166(2):211-218
- View full text via DOI
Merkliste

22
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial

von Post, C ; De Boer, S ; Powell, M ; et al.

Schlagworte: endoometrial cancer, chemotherapy, radiotherapy, molecular classification; info:eu-repo/semantics/article
- Zum Volltext über OAIster
Merkliste

23
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

von Olawaiye, A ; Gladieff, L ; O'Malley, D ; et al.

Schlagworte: chemotherapy; info:eu-repo/semantics/article
- Zum Volltext über OAIster
Merkliste

24
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)

von Friedlander, M. ; Benson, C. ; O'Connell, R.L. ; et al.

In Gynecologic Oncology April 2021 161(1):160-165
- View full text via DOI
Merkliste

25
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

von Kang, Eun Young ; Cheasley, Dane ; LePage, Cecile ; et al.

In Modern Pathology January 2021 34(1):194-206
- View full text via DOI
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag